Rekah Pharmaceutical Industry Stock Net Income
| REKA Stock | ILA 1,378 12.00 0.86% |
Rekah Pharmaceutical Industry fundamentals help investors to digest information that contributes to Rekah Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Rekah Stock. The fundamental analysis module provides a way to measure Rekah Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rekah Pharmaceutical stock.
Rekah |
Rekah Pharmaceutical Industry Company Net Income Analysis
Rekah Pharmaceutical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Rekah Pharmaceutical Net Income | 6.62 M |
Most of Rekah Pharmaceutical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Rekah Pharmaceutical Industry reported net income of 6.62 M. This is 98.06% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all Israel stocks is 98.84% higher than that of the company.
Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Rekah Fundamentals
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 263.95 M | |||
| Gross Profit | 65.16 M | |||
| EBITDA | 36.2 M | |||
| Net Income | 6.62 M | |||
| Cash And Equivalents | 31.61 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 101.23 M | |||
| Debt To Equity | 1.01 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | 14.39 X | |||
| Cash Flow From Operations | 21.17 M | |||
| Earnings Per Share | 0.32 X | |||
| Number Of Employees | 399 | |||
| Beta | 0.0605 | |||
| Market Capitalization | 193.93 M | |||
| Total Asset | 437.09 M | |||
| Retained Earnings | 49 M | |||
| Working Capital | 156 M | |||
| Current Asset | 246 M | |||
| Current Liabilities | 90 M | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 437.09 M | |||
| Last Dividend Paid | 0.87 |
About Rekah Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rekah Pharmaceutical Industry's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rekah Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rekah Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rekah Pharmaceutical's short interest history, or implied volatility extrapolated from Rekah Pharmaceutical options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rekah Pharmaceutical Industry. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |